BCL2 and Miyoshi myopathy: Treatment of glutamine-deprived MM or 6-diazo-5-oxo-L-norleucine (DON)-treated MM patient samples and MM cell lines with the BCL-2 antagonist venetoclax (ABT-199) resulted in increased apoptosis.